Maria Pelecanou

Dr. Maria Pelecanou

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2020 in Dalton Transactions
Verified
Journal Article
Closed access
PDF file
Eleftherios HalevasEleftherios Halevas
Eleftherios Halevas
BMBarbara Mavroidi
Barbara Mavroidi
OAOrestis Antonoglou
Orestis Antonoglou
AHAntonios Hatzidimitriou
Antonios Hatzidimitriou
MSMarina Sagnou
Marina Sagnou
MPMaria Pelecanou
Maria Pelecanou
Chemotherapeutic metal-based compounds are effective anticancer agents; however, their cytotoxic profile and significant side effects limit their wide application. Natural products, especially flavonoids, are a prominent alternative source of anticancer agents that can be used as ligands for the generation of new bioactive complexes with metal ions of known biochemical and pharmacological activities. Herein, we present the synthesis and detailed structural and physicochemical characterizations of three novel complex assemblies of Ga(III) with the flavonoid chrysin and the ancillary aromatic chelators 1,10-phenanthroline, 2,2′-bipyridine and imidazole. The complexes constitute the only crystallographically characterized structures having a metal core from the boron group elements and a flavonoid as the ligand. The in vitro biological evaluation of the three complexes in a series of cancer cell lines of different origin established their cytotoxicity and ROS generating potential. In particular, the Ga(III)–chrysin–imidazole complex displayed the highest anticancer efficacy against all cancer cell lines with IC50 values in the low micromolar range (<1.18 μM), a result worth further investigation.

1 July 2020 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MSMarina Sagnou
Marina Sagnou
Fedor NovikovFedor Novikov
Fedor Novikov
EIEkaterina Ivanova
Ekaterina Ivanova
PAPolyxeni Alexiou
Polyxeni Alexiou
VSVictor S. Stroylov
Victor S. Stroylov
GCGhermes G. Chilov
Ghermes G. Chilov

19 June 2022 in Brain Sciences
Verified
Journal Article
Open access
PDF file
BMBarbara Mavroidi
Barbara Mavroidi
Archontia KaminariArchontia Kaminari
Archontia Kaminari
Dimitris MatiadisDimitris Matiadis
Dimitris Matiadis
Dimitra Hadjipavlou-LitinaDimitra Hadjipavlou-Litina
Dimitra Hadjipavlou-Litina
MPMaria Pelecanou
Maria Pelecanou
MSMarina Sagnou
Marina Sagnou
Alzheimer’s disease (AD) is a multifactorial disorder strongly involving the formation of amyloid-β (Aβ) oligomers, which subsequently aggregate into the disease characteristic insoluble amyloid plaques, in addition to oxidative stress, inflammation and increased acetylcholinesterase activity. Moreover, Aβ oligomers interfere with the expression and activity of Glycogen synthase kinase-3 (GSK3) and Protein kinase B (PKB), also known as AKT. In the present study, the potential multimodal effect of two synthetic isatin thiosemicarbazones (ITSCs), which have been previously shown to prevent Aβ aggregation was evaluated. Both compounds resulted in fully reversing the Aβ-mediated toxicity in SK-NS-H cells treated with exogenous Aβ peptides at various pre-incubation time points and at 1 μM. Cell survival was not recovered when compounds were applied after Aβ cell treatment. The ITSCs were non-toxic against wild type and 5xFAD primary hippocampal cells. They reversed the inhibition of Akt and GSK-3β phosphorylation in 5xFAD cells. Finally, they exhibited good antioxidant potential and moderate lipoxygenase and acetylcholinesterase inhibition activity. Overall, these results suggest that isatin thiosemicarbazone is a suitable scaffold for the development of multimodal anti-AD agents.

15 February 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MSMarina Sagnou
Marina Sagnou
BMBarbara Mavroidi
Barbara Mavroidi
Antonio SheganiAntonio Shegani
Antonio Shegani
MPMaria Paravatou-Petsotas
Maria Paravatou-Petsotas
Catherine RaptopoulouCatherine Raptopoulou
Catherine Raptopoulou
MPMaria Pelecanou
Maria Pelecanou

1 August 2018 in Dental Materials
Verified
Journal Article
Closed access
MDMaria Dimitriadi
Maria Dimitriadi
APAngeliki Panagiotopoulou
Angeliki Panagiotopoulou
MPMaria Pelecanou
Maria Pelecanou
KYKonstantina Yannakopoulou
Konstantina Yannakopoulou
GEORGE ELIADESGEORGE ELIADES
GEORGE ELIADES

29 June 2020 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
MSMarina Sagnou
Marina Sagnou
BMBarbara Mavroidi
Barbara Mavroidi
Archontia KaminariArchontia Kaminari
Archontia Kaminari
NBNikos Boukos
Nikos Boukos
MPMaria Pelecanou
Maria Pelecanou